The perceptions of cancer health-care practitioners in New Zealand and the USA toward psychedelic-assisted therapy with cancer patients: A cross-sectional survey.
Reynolds L, Barnett B, Weleff J, Morunga E, Wells A, Stack A, Akroyd A, Hoeh N, Sundram F, Muthukumaraswamy S, Lawrence N, Evans W. The perceptions of cancer health-care practitioners in New Zealand and the USA toward psychedelic-assisted therapy with cancer patients: A cross-sectional survey. Palliative & Supportive Care 2022, 1-10. PMID: 36325995, DOI: 10.1017/s1478951522001481.Peer-Reviewed Original ResearchHealth-care practitionersCross-sectional surveyPsychedelic-assisted therapyPatients to trialsIndigenous perspectives of healthEnd-of-life contextCancer patientsEnd-of-lifePerspective of healthVulnerable cancer patientsMind-altering experiencesNew Zealand participantsExistential distressConvenience sampleNew ZealandPsychedelic treatmentParticipantsPractitionersNew Zealand samplePerceptionCancerPatientsZealandAdvanced diseaseTrialsPsychedelics in the Treatment of Substance Use Disorders
Barnett B, Weleff J. Psychedelics in the Treatment of Substance Use Disorders. Psychiatric Annals 2022, 52: 365-370. DOI: 10.3928/00485713-20220804-01.Peer-Reviewed Original ResearchSubstance use disordersPsychedelic experienceTreatment of substance use disordersLysergic acid diethylamideSubjective effectsUse disorderAcid diethylamidePlacebo-controlled trialPsychedelicsBehavioral changesTherapeutic potentialClinician concernsLife narrativesDisordersFacilitation programTreatment paradigmTherapeutic efficacyClinical trialsTreatment potentialObservational studyPsilocybinDiethylamideTrialsSubstancesOpioid